General Hematology
SR | Laser therapy for retinopathy in sickle cell disease
12 Jan, 2023 | 13:02h | UTCLaser therapy for retinopathy in sickle cell disease – Cochrane Library
Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library
Review | Antithrombotic therapy after bioprosthetic aortic valve replacement
12 Jan, 2023 | 12:51h | UTC
Review | Platelet transfusion for trauma resuscitation
11 Jan, 2023 | 14:08h | UTCPlatelet Transfusion for Trauma Resuscitation – Current Trauma Reports
Special Issue | American Society of Hematology Education Program (series of open-access review articles)
10 Jan, 2023 | 14:26h | UTCHomepage: American Society of Hematology Education Program – Hematology
Chronic lymphocytic leukemia treatment algorithm 2022
10 Jan, 2023 | 14:05h | UTCChronic lymphocytic leukemia treatment algorithm 2022 – Blood Cancer Journal
Updated Guidance | Acute, periprocedural and long-term antithrombotic therapy in older adults.
16 Dec, 2022 | 13:51h | UTCCommentary: Antithrombotic Therapy in Older Adults: Key Points – American College of Cardiology
RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.
16 Dec, 2022 | 13:15h | UTC
Major hemorrhage: past, present and future.
13 Dec, 2022 | 14:05h | UTCMajor haemorrhage: past, present and future – Anaesthesia
M-A | Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage.
9 Dec, 2022 | 13:17h | UTC
Commentary on Twitter
Meta-analysis finds mostly successful DOAC reversal with 4F-PCC (77%), andexanet alfa (AA)(75%), and idarucizumab (82%) in patients with ICH. 4F-PCC and AA had comparable success in factor Xa inhibitor reversal, mortality, and thromboembolic outcomes. #OA https://t.co/aieJd9h5jo
— JAMA Network Open (@JAMANetworkOpen) November 4, 2022
Preliminary study suggests that Edoxaban is a safe alternative for preventing thromboembolism in pediatric patients with cardiac disease.
9 Dec, 2022 | 13:07h | UTCEdoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Cohort Study | Cutaneous involvement in catastrophic antiphospholipid syndrome.
8 Dec, 2022 | 12:53h | UTCCutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients – JAMA Dermatology (free for a limited period)
Commentary on Twitter
In this cohort study, half of patients with catastrophic APS (CAPS) showed cutaneous involvement, with a spectrum of clinical presentations, including distal inflammatory edema. Skin biopsies confirmed diagnosis in all but 1 biopsied patient. https://t.co/lwBL3lyLxT
— JAMA Dermatology (@JAMADerm) December 7, 2022
RCT | Fostamatinib for the treatment of patients with primary immune thrombocytopenia.
7 Dec, 2022 | 14:18h | UTC
RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.
2 Dec, 2022 | 14:24h | UTCRivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence
Commentary on Twitter
This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz#LiverTwitter pic.twitter.com/bgN1QS171j
— NEJM Evidence (@NEJMEvidence) November 22, 2022
Cohort Study | Trends and risk factors for venous thromboembolism among hospitalized medical patients.
29 Nov, 2022 | 14:04h | UTC
Commentary on Twitter
1.2% of hospitalized patients developed a hospital-associated venous thromboembolism (HA-VTE), slightly increasing from 2013-2016 (1.1-1.6%). 78% happened after discharge; HA-VTE were linked to higher risk of readmission and death. @KPDOR https://t.co/cB8VhY7k7X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) November 21, 2022
RCT | Anticoagulation for 3 months reduces recurrence rates vs. treatment for 6 weeks in patients with isolated distal DVT.
24 Nov, 2022 | 13:34h | UTCNews Release: Extending anti-clotting treatment after distal DVT reduces further clot risk – BMJ Newsroom
SR | Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.
24 Nov, 2022 | 13:24h | UTC
RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome.
22 Nov, 2022 | 13:12h | UTC
M-A | Prophylactic platelet transfusions vs. no prophylaxis in hospitalized patients with thrombocytopenia.
21 Nov, 2022 | 13:59h | UTC
RCT | A small study tested Apixaban’s efficacy and safety versus a Vitamin K-antagonist in patients on chronic hemodialysis.
11 Nov, 2022 | 13:52h | UTCRelated Study: Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial – Circulation
RCT | Intermediate-dose no better than low-dose LMWH in pregnant and post-partum women with previous thromboembolism.
10 Nov, 2022 | 14:12h | UTCIntermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial https://t.co/9zHeUIda7o
— Saskia Middeldorp (@MiddeldorpS) October 28, 2022
M-A | DOACs increase the risk of arterial thrombosis vs. Vitamin-K antagonists in antiphospholipid syndrome.
9 Nov, 2022 | 12:28h | UTCDirect Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Observational study suggests Apixaban for AF is associated with a lower risk of GI bleeding vs. other DOACs.
3 Nov, 2022 | 13:32h | UTCComparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Best blood thinner for minimizing bleeding risk identified – University College London
Commentary: GI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib – HealthDay
Dose-reduced direct oral anticoagulants: practical considerations.
31 Oct, 2022 | 13:52h | UTC
RCT | Sutimlimab in patients with cold agglutinin disease without recent transfusion.
31 Oct, 2022 | 13:37h | UTCEditorial: A virtuosic CADENZA played by sutimlimab – Blood
Commentary: Sutimlimab Shows Efficacy in Patients With CAD Without Recent Transfusion – AJMC
Commentary on Twitter
Read #openaccess article ‘Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial’ recently published in @BloodJournalhttps://t.co/K13e9V1c0K @ASH_Hematology pic.twitter.com/61oqWewcJ2
— Elsevier Hematology (@ELShematology) September 12, 2022
Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.
31 Oct, 2022 | 13:34h | UTCCommentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition